ArticleCytotechnology2026
ITGB2 promotes HIF-1α/GLUT1 mediated glucose metabolic reprogramming in renal tubular epithelial cells to aggravate the progression of diabetic kidney disease.
Article in Cytotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic kidney disease (DKD) is characterized by tubular metabolic remodeling, inflammation, and profibrotic injury. However, whether integrin β2 (ITGB2) links high-glucose (HG) stress to hypoxia-inducible factor-1α (HIF-1α)/glucose transporter 1 (GLUT1)-dependent metabolic reprogramming in renal tubular epithelial cells remains unclear. This study investigated the role and underlying mechanism of the ITGB2/HIF-1α/GLUT1 axis in HG-induced tubular injury. ITGB2 expression was first examined in the publicly available human renal transcriptomic dataset GSE30529. HK-2 cells were cultured under normal-glucose, HG, or mannitol osmotic-control conditions. ITGB2 was silenced or overexpressed, and HIF1A or SLC2A1/GLUT1 was knocked down by siRNA. Protein expression, HIF-1α nuclear accumulation, and HIF-1α protein stability were assessed by western blotting, subcellular fractionation, and cycloheximide-chase assays. Metabolic remodeling was evaluated by 2-NBDG uptake, lactate production, extracellular acidification rate (ECAR), oxygen consumption rate (OCR), and ATP content. Tubular injury, inflammatory, and EMT-like/profibrotic phenotypes were assessed by ELISA and RT-qPCR. Dual-luciferase reporter and chromatin immunoprecipitation assays were performed to evaluate HIF-1α-mediated transcriptional regulation of GLUT1. ITGB2 expression was increased in the tubulointerstitial compartment of human diabetic kidneys in GSE30529. In HK-2 cells, HG increased ITGB2, HIF-1α, and GLUT1 expression, accompanied by increased glucose uptake, lactate production, ECAR, and ATP content and reduced OCR, together with enhanced tubular injury, inflammatory, and EMT-like/profibrotic responses. ITGB2 knockdown reduced HIF-1α/GLUT1 expression and nuclear HIF-1α accumulation and accelerated HIF-1α protein decay, suggesting that ITGB2 contributes to HIF-1α protein stability. HIF-1α directly bound to and transcriptionally activated the GLUT1 promoter. ITGB2 overexpression further enhanced metabolic reprogramming and pathological phenotypes, whereas HIF1A or SLC2A1 silencing markedly attenuated these effects. ITGB2 promotes HIF-1α/GLUT1-dependent metabolic reprogramming and contributes to tubular injury, inflammatory, and EMT-like/profibrotic responses in HG-treated HK-2 cells. These findings support a role for the ITGB2/HIF-1α/GLUT1 signaling axis in coordinating metabolic and pathological responses under HG conditions. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s10616-026-01076-7.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.